EC has granted marketing authorization for OBGEMSA™ in overactive bladder
The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particularly debilitating condition affecting over 70 million patients in Europe. In 2022, Pierre Fabre…